MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Vesicle monamine transporter(VMAT2)"

  • 2016 International Congress

    Cognitive and depressive behavior changes in aged mice with heterozygous deletions of VMAT2 or of DAT

    K. Ma, J. Huang, L. Liu, H. Jiang, X. Xu, C. Han, Y. Shen, Y. Xia, S. Guo, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

    Objective: To evaluate cognitive and depressive behavior in aged mice with heterozygous deletions of vesicular monoamine transporter (VMAT2) or of Dopamine transporter (DAT). Background: VMAT2…
  • 2016 International Congress

    A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome

    J. Jankovic, J. Jimenez-Shahed, C. Budman, B. Coffey, T.K. Murphy, D. Shprecher, D. Stamler (Houston, TX, USA)

    Objective: This study explored the safety, tolerability and preliminary efficacy of SD-809 (deutetrabenazine) in adolescents with moderate to severe tics associated with Tourette syndrome (TS).…
  • 2016 International Congress

    KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia

    S.A. Factor, R.A. Hauser, S. Siegert, G.S. Liang, C.F. O'Brien (Atlanta, GA, USA)

    Objective: To assess the efficacy, safety and tolerability of valbenazine (NBI-98854) for Tardive Dyskinesia (TD). Background: Tardive dyskinesia (TD) is a persistent and often disabling…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29077 (not found)
  • #29056 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28189 (not found)
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley